Holen Sie sich die Stockscreener-App
4.38
0.68%
-0.03
Handel nachbörslich:
4.38
Schlusskurs vom Vortag:
$4.41
Offen:
$4.45
24-Stunden-Volumen:
558.49K
Relative Volume:
0.17
Marktkapitalisierung:
$499.03M
Einnahmen:
$884.00K
Nettoeinkommen (Verlust:
$-103.64M
KGV:
-3.1411
EPS:
-1.3944
Netto-Cashflow:
$-95.45M
1W Leistung:
+14.36%
1M Leistung:
-11.87%
6M Leistung:
+23.38%
1J Leistung:
+143.33%
1-Tages-Spanne:
$4.30
$4.58
1-Wochen-Bereich:
$3.97
$4.58
52-Wochen-Spanne:
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.38 | 502.45M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
102.30 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.30 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.19 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline - TipRanks
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026 - TradingView
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline - stocktitan.net
Revenue Check: Can Perspective Therapeutics Inc grow without dilution2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
Analyst Upgrade: Can Perspective Therapeutics Inc expand into new marketsRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
Perspective Therapeutics, Inc.(NYSEAM:CATX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
If You Invested $1,000 in Perspective Therapeutics Inc (CATX) - stocktitan.net
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CATX Should I Buy - Intellectia AI
Perspective Therapeutics Q1 EPS Boosted by Brookline Cap M - MarketBeat
Jones Trading reiterates Perspective Therapeutics stock Buy rating By Investing.com - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Lantheus (LNTH), Perspective Therapeutics (CATX) - The Globe and Mail
Jones Trading reiterates Perspective Therapeutics stock Buy rating - Investing.com
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | CATX Stock News - GuruFocus
B. Riley Financial Issues Positive Forecast for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price - MarketBeat
Perspective Therapeutics (CATX) Receives Analyst Rating Boost | - GuruFocus
Perspective Therapeutics (CATX) Receives Boost from UBS with Rai - GuruFocus
Perspective Therapeutics price target raised to $13 from $11 at B. Riley - TipRanks
UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating - marketscreener.com
UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock - MarketBeat
Perspective Therapeutics (CATX) Rating Reiterated by Wedbush | C - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Receives Outperform Rating from Wedbush - MarketBeat
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT) - The Globe and Mail
B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating - marketscreener.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 - The Manila Times
Perspective Therapeutics (CATX) to Release Earnings on Wednesday - MarketBeat
RBC cuts Perspective Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Perspective Therapeutics Q4 2025 earnings preview - MSN
Truist reiterates Buy on Perspective Therapeutics stock By Investing.com - Investing.com Canada
BTIG Reiterates Buy Rating for CATX with $14 Price Target | CATX Stock News - GuruFocus
Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00 - MarketBeat
RBC Capital Lowers Price Target for CATX While Maintaining 'Outp - GuruFocus
Truist reiterates Buy on Perspective Therapeutics stock - Investing.com
RBC cuts Perspective Therapeutics stock price target on model updates - Investing.com
Perspective Therapeutics stock rating reiterated at Buy by BTIG - Investing.com South Africa
Oppenheimer reiterates Perspective Therapeutics stock rating at Outperform By Investing.com - Investing.com South Africa
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.12%
Kapitalisierung:
|
Volumen (24h):